The information contained in this announcement is deemed by the company and Renalytix AI Plc to constitute inside information as stipulated under the EU market abuse regulation (596/2014). upon publication of the announcement via a regulatory information service, this information is considered to

Mount Sinai Health System (MSHS) and Renalytix AI Plc today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale